Private equity firm Kedaara Capital has invested $200 million in Tynor Orthotics, a major Indian manufacturer of orthopedic and rehabilitation products. The deal supports the company’s global expansion and marks the exit of investor Lighthouse Funds. As Tynor is an unlisted company, there is no direct impact on the stock market, though the deal highlights growing activity in India’s specialized medical device sector.
Private equity firm Kedaara Capital has announced an investment of $200 million in Tynor Orthotics Private Limited. This capital infusion is designed to help the Mohali-based medical device manufacturer accelerate its expansion into international markets, upgrade its manufacturing facilities, and solidify its position as a global player in the orthotics and wellness space.
The investment also marks the end of an eight-year partnership with Lighthouse Funds, which has exited its investment in the company. Tynor Orthotics, established in 1993, has built a vast distribution network over the decades. The company currently reaches consumers through more than 300,000 retail outlets and 8,000 hospitals across 60 countries, claiming its products have been used by over 100 million individuals.
Fueling Global Manufacturing Ambitions
The partnership aims to combine Tynor’s existing manufacturing capabilities—which include three facilities spanning 6.5 lakh square feet—with Kedaara Capital’s expertise in scaling businesses. A core objective of this capital injection is to deepen Tynor’s supply-chain presence in the "Global North." This strategy is also supported by the company’s long-standing relationship with the French firm Thuasne Group, which remains a key strategic partner.
From a financial perspective, Tynor reported a revenue of approximately ₹495.5 crore and a profit of ₹73.4 crore for the fiscal year 2024. These figures offer insight into the company’s current scale as it enters a new phase of international growth and capacity enhancement.
Investor Context and Monitorables
Because Tynor Orthotics is a private, unlisted company, its shares are not traded on public stock exchanges like the NSE or BSE. Consequently, there is no direct stock market reaction or share price movement for public investors to track.
However, the deal is significant for understanding the broader trends in the Indian medical devices sector, which is seeing increasing interest from private equity firms. As Tynor works to scale its operations, the key areas for observers to track will include the execution of its international expansion strategy and the effective use of the new capital to upgrade manufacturing. Like any company in the medical device space, Tynor will also need to manage operational risks such as navigating different international healthcare regulations, maintaining product quality standards, and protecting profit margins against potential fluctuations in raw material costs and currency volatility.